01—Abstract
Summary
Summary of the 8-K filed May 13, 2024. Cited figures are marked; the original filing is the authoritative source.
Humana Inc. disclosed in this Form 8-K that James A.
Rechtin will become President and Chief Executive Officer effective July 1, 2024, succeeding Bruce D. Broussard. The company had previously announced on October 11, 2023 that Broussard would step down in the latter half of 2024, and it now states the transition date is expected to be July 1, 2024.
Rechtin joined Humana as President and Chief Operating Officer in January 2024 as part of a long-planned CEO transition. Under a Transition & Separation Agreement dated May 13, 2024 (Exhibit 10.1), Broussard will provide strategic advisory services after the Transition Date until March 1, 2025, then move to the company's variable staffing pool (temporary worker status) until March 1, 2026. During that period he will serve on the Board of The Humana Foundation, advise the Foundation, including on its partnership with the Trust for the National Mall, and give general strategic advice to the company.
He will receive no salary and no additional compensation or benefits beyond continued vesting of equity under the stock incentive plan and generally available programs, and he is not entitled to severance under the Executive Severance Policy. Broussard is also expected to resign from the Board and Rechtin is expected to join it, both effective July 1, 2024. The filing states Broussard's resignation is not the result of any dispute or disagreement with the company or its Board.
The accompanying press release (Exhibit 99.1) quotes Board Chairman Kurt Hilzinger expressing confidence that Rechtin is ready to assume the role, and quotes Rechtin describing the company's growth prospects and his commitment to operational improvement and long-term shareholder value. The release describes Rechtin's background, including prior roles at Envision Healthcare, OptumCare, and DaVita Medical Group, and more than 22 years of healthcare experience with a focus on value-based care and Medicare Advantage.
02—Key points
Key Highlights
- James A. Rechtin will become President and CEO of Humana effective July 1, 2024, succeeding Bruce D. Broussard.
- The CEO transition date was set at July 1, 2024, earlier than the 'latter half of 2024' timing first announced on October 11, 2023.
- Rechtin joined Humana as President and Chief Operating Officer in January 2024 and has worked with Broussard during the onboarding period.
- Broussard will provide strategic advisory services until March 1, 2025, then serve as a variable staffing pool temporary worker until March 1, 2026.
- Broussard will receive no salary during the variable staffing pool period and no severance under the Executive Severance Policy; equity continues to vest under the stock incentive plan.
- Broussard will resign from the Board and Rechtin will join the Board, both effective July 1, 2024; the filing states the resignation involves no dispute or disagreement.
- Rechtin brings more than 22 years of healthcare experience, including a focus on value-based care and Medicare Advantage, according to the press release.
03—Questions
Frequently Asked Questions
Who will lead Humana after July 1, 2024?
James A. (Jim) Rechtin, currently President and Chief Operating Officer, will assume the role of President and Chief Executive Officer effective July 1, 2024, succeeding Bruce D. Broussard.
What will Bruce Broussard do after stepping down as CEO?
Under a Transition & Separation Agreement dated May 13, 2024, Broussard will provide strategic advisory services until March 1, 2025, then serve in the company's variable staffing pool until March 1, 2026. During that period he will remain on the Board of The Humana Foundation, advise the Foundation, and provide general strategic advice to the company.
Will Broussard receive severance or additional compensation?
No. The filing states Broussard will not receive any additional compensation or benefits beyond continued equity vesting under the stock incentive plan and generally available compensation and benefit programs. He is not entitled to severance under the Executive Severance Policy, and he will not receive a salary during the variable staffing pool period.
Is Broussard's departure related to any disagreement with the company?
The filing states that Broussard's expected resignation from the Board is not the result of any dispute or disagreement with the company or its Board on any matter relating to its operations, policies or practices.
What is Rechtin's background?
According to the press release, Rechtin previously served as President and CEO of Envision Healthcare, President of OptumCare (part of UnitedHealth Group), and in roles at DaVita Medical Group. He has more than 22 years of healthcare experience focused on value-based care, including Medicare Advantage, and earlier spent 14 years with Bain & Company in the healthcare sector.
04—Continue